FIGURE 2.

Kaplan–Meier plot of time to inadequate glycaemic control with liraglutide versus post hoc OAD subgroups*. *OADs included investigator‐selected drugs from the classes: α‐glucosidase inhibitor, DPP‐4i, SGLT‐2i, SU, or thiazolidinedione; both liraglutide and OADs were prescribed in combination with metformin. Full analysis set. The primary endpoint of time to inadequate glycaemic control was defined as HbA1c > 7.0% (>53 mmol/mol) at two consecutive scheduled visits after the first 26 weeks of treatment and up to 104 weeks. The first possible occurrence was at the week 38 visit. Test for no treatment difference was based on using a generalized log rank test for interval censored failure time data. DPP‐4i, dipeptidyl peptidase‐4 inhibitor; SGLT‐2i, sodium‐glucose co‐transporter‐2 inhibitor; SU, sulphonylurea